Depresión. Uso de antidepresivos en una oficina de farmacia rural

  1. Chaxiraxi Morales Marrero 1
  2. María del Carmen Padrón 1
  3. Susana Abdala Kuri 1
  4. Alexis Manuel Oliva Martín 2
  5. Sandra Dévora Gutiérrez 1
  1. 1 Departamento de Medicina Física y Farmacología, Facultad de Farmacia. Universidad de La Laguna. España
  2. 2 Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de La Laguna. España
Journal:
Majorensis: Revista Electrónica de Ciencia y Tecnología

ISSN: 1697-5529

Year of publication: 2021

Issue: 17

Pages: 59-65

Type: Article

Export: RIS

Abstract

Introduction: Given the growing demand for antidepressants in recent years, it is necessary to quantify from the pharmacy office their consumption and rational use by polymedicated patients who go to health centers demanding their prescription. Materials and methods: Antidepressant drug dispensations were collected month to month for one year and classified by active ingredient and dose, as well as by generic or brand name. The data were obtained from pharmaceutical management software Farmatic V12 and they were analyzed using the Microsoft Office Excel 2010 program. Results and discussion: A total of 3,662 dispensations of the group "N06A. Antidepressants" were quantified. Only 9 out of every 17 molecules collected have a homogeneous set, the generic reference being of choice at the time of dispensing, since in these cases only 37.73% was dispensed as a trademark. The most commonly used subgroup of antidepressants was the selective serotonin reuptake inhibitors (SSRIs) (45.47%), which included escitalopram as the most commonly used active ingredient (22.26 DHD), followed by sertraline, paroxetine, fluoxetine and citalopram. Conclusions: Escitalopram has become the active reference for the treatment of depressive disorders, both in primary care and specialist physicians. The high consumption figures of this therapeutic group need the work of the community pharmacist to try to determine if these are justified by a better detection and diagnosis from primary care consultations or, if on the contrary, respond to a clear situation of overdiagnosis and overtreatment.

Bibliographic References

  • Agencia Española de Medicamentos y Productos Sanitarios. Abril 2005. Nota informativa 2005/09 de la AEMPS sobre Uso de ISRS y otros antidepresivos en niños y adolescentes. (Actualización de las Notas Informativas 2004/06 y 2004/14 de la AEMPS). Disponible en: http://www.aemps.gob.es/informa/notasInformati vas/medicamentosUsoHumano/seguridad/2005/ NI_2005-09_ISRS_antidepresivos.htm.
  • Agencia Española de Medicamentos y Productos Sanitarios. Diciembre 2011. Nota Informativa Escitalopram: prolongación del intervalo QT del electrocardiograma. Ref. MUH (FV), 23/2011. Disponible en: http://www.aemps.gob.es/informa/notasInformati vas/medicamentosUsoHumano/seguridad/2011/ NI-MUH_23-2011.htm.
  • Agencia Española de Medicamentos y Productos Sanitarios. Disponible en: http://www.aemps.gob.es/informa/boletinMensu al/2012/noviembre/informe medicamentos.htm.
  • Agencia Española de Medicamentos y Productos Sanitarios. Informe de utilización de medicamentos U/AD/V1/14012015. Utilización de medicamentos antidepresivos en España durante el periodo 2000-2013. 2015. Pp. 1-4.
  • Agencia Española de Medicamentos y Productos Sanitarios. Junio 2001. Bupropion. Nota del Comité de Seguridad de Medicamentos relativa al Bupropion y riesgo de convulsiones. Ref. 2001/04. Disponible en: http://www.aemps.gob.es/informa/notasInformati vas/medicamentosUsoHumano/seguridad/2001/ NI_2001-04_bupropion.htm.
  • Altshuler LL, Hendrich V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry, 1998; 59: 29.
  • Arranz Estevez FJ, Domenech Bisen JR. Antidepresivos. Neurofarmacología contemporánea. Ed. Elsevier, 2011; Barcelona. Pp. 219- 46.
  • Bourin M, David DJ, Jolliet P, et al. Mechanism of action of antidepressants and therapeutic perspectives. Therapie. 2002; 57(4): 385-96.
  • Bourin M, Prica C. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Curr Pharm Des, 2009; 15(14): 1675‐82.
  • Cassano P, Fava M. Depression and public health, an overview. J Psychosom Res, 2002; 53: 849- 57.
  • Centro de Información de Medicamentos de Uso Humano. Agencia Española de Medicamentos y productos sanitarios.
  • Comité de evaluación de nuevos medicamentos de Euskadi. Informe de evaluación. Agomelatina. Departamento de Sanidad y Consumo del Gobierno Vasco. Disponible en: http://www.osakidetza.euskadi.eus/contenidos/in formacion/cevime_nuevo_medicamento/es_nme/ adjuntos/agomelatina_informe_c.pdf.
  • Departamento Técnico del Consejo General de Colegios Oficiales de Farmacéuticos. Catalogo de Medicamentos. Colección Consejo 2015, Ed. Consejo General de Colegios Oficiales de Farmacéuticos. Madrid. 2015. Pp. 2386-443.
  • European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use. Withdrawal assessment report for ellefore. International Nonproprietary Name: Desvenlafaxine Procedure No. EMEA/H/C/932. London, 22 January 2009 Doc. Ref: EMEA/45054/2009.
  • Fiedorowicz JG, Swartz KL. The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice. J Psychiatr Pract, 2004; 10(4): 239-48.
  • Grupo de trabajo de la Guía de Practica Clínica sobre el Manejo de la Depresión en el Adulto. Guía de Practica Clínica sobre el Manejo de la Depresión en el Adulto. Agencia de Evaluación de Tecnologías Sanitarias de Galicia, avalia-t. Conselleria de Sanidade. Ministerio de Sanidad, Servicios Sociales e Igualdad. Galicia (avalia-t), 2014. Pag. 35.
  • Haro JM, Palacin C, Vilagut G, et al. Grupo ESEMeD-Espana. Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain study. Med Clin (Bar), 2006; 126(12): 445-51.
  • Lopez-Lanza J M, Villa Puente R, López Videras I et al. Manejo en atención primaria de un primer episodio depresivo. Uso de antidepresivos y derivaciones. Medicina de Familia Semergen, 2016; 42(2): 88-93.
  • Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res and Opin, 2009; 25: 161-75.
  • Montero Fernandez, MJ. Mirtazapina. Hoja de evaluación de medicamentos de Castilla La Mancha. SESCAM, 2002; 2(3): 1-3.
  • Moore RA, Derry S, Aldington D, Cole P, et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Sys Rev, 2012; 12; 12: CD008242.
  • Nemeroff CB, Entsuah R, Benattia I, Demitrack M, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry, 2008; 63: 424-34.
  • Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry, 2007; 62: 1217-27.
  • Poluzzi E, Piccinni C, Sangiorgi E, et al. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. Eur J of Clin Pharmacol, 2013; 69(12): 2095- 101.
  • Psych Central. Top 25 Psychiatric Prescriptions for 2009 in the US. Disponible en:http://psychcentral.com/lib/top-25- psychiatric-prescriptions-for-2009/0003170.
  • Rohan KJ, Lindsey KT, Roecklein KA, et al. Cognitive-behavioral therapy, light therapy and their combination in treating seasonal affective disorder. J Affect Disord, 2004; 80: 273-83.
  • Saiz Ruiz J, Montes Rodríguez JM. Tratamiento farmacológico de la depresión. Rev Clin Esp, 2005; 205: 233-40.
  • Sempere Verdu E, Salazar Fraile J, Palop Larrea V, et al. Evolución de la utilización de antidepresivos, ansiolíticos e hipnóticos en la Comunitat Valenciana. Periodo 2000-2010. Aten Prim, 2014; 46(8): 416-25.
  • Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry, 2002; 180: 396-404.
  • Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vas Health Risk Managt, 2007; 3(6): 833-44.
  • Vicens C, Sempere E, Arroyo P, et al. Trends in benzodiazepine and antidepressant use in three Spanish regions, 2005-2010. WPA Thematic Conference. Mental Health and Family Medicine Working Together. Granada 8-11. Febrero 2012.
  • WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC. Index 2017